Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-κB

Prostate

Volumn 61, Issue 2, 2004, Pages 105-113

  Raj, Ganesh V ^a   Sekula, Jeffrey A ^a   Guo, Rishu ^a   Madden, John F ^a   Daaka, Yehia ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; G protein coupled receptor; LPA; NF B; Prostate cancer

Indexed keywords

ANDROGEN; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; LYSOPHOSPHATIDIC ACID; PROPIDIUM IODIDE; PROTEIN KINASE B;

ARTICLE; CANCER CELL; CELL ACTIVATION; CELL CYCLE PARAMETERS; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION;

ADENOCARCINOMA; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; LYSOPHOSPHOLIPIDS; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 4544357634     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20083     Document Type: Article

References (38)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53(1):5-26.
2. Chodak GW, Keane T, Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002;60(2):201-208.
3. Isaacs W, De Marzo A, Nelson W. Focus on prostate cancer. Cancer Cell 2002;2(2):113.
4. Lara PN Jr., Meyers FJ. Treatment options in androgen-independent prostate cancer. Cancer Invest 1999;17(2):137-144.
5. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1(1):34-45.
6. Mercurio F, Manning AM. Multiple signals converging on NF-kappaB. Curr Opin Cell Biol 1999;11(2):226-232.
7. Rothwarf DM, Karin M. The NF-kappa B activation pathway: A paradigm in information transfer from membrane to nucleus. Sci STKE 1999;1999(5):RE1.
8. Karin M. The beginning of the end: IkappaB kinase (IKK) and NF-kappaB activation. J Biol Chem 1999;274(39):27339-27342.
9. Amit S, Ben-Neriah Y. NF-kappaB activation in cancer: A challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol 2003;13(1):15-28.
10. Chen CD, Sawyers CL. NF-κB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002;22(8):2862-2870.
11. Lindholm PF, Bub J, Kaul S, Shidham VB, Kajdacsy-Balla A. The role of constitutive NF-kappaB activity in PC-3 human prostate cancer cell invasive behavior. Clin Exp Metastasis 2000;18(6): 471-479.
12. Daaka Y. G proteins in cancer: The prostate cancer paradigm. Sci STKE 2004; re3.
13. Xu LL, Stackhouse BG, Florence K, Zhang W, Shanmugam N, Sesterhenn IA, Zou Z, Srikantan V, Augustus M, Roschke V, Carter K, McLeod DG, Moul JW, Soppett D, Srivastava S. PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res 2000;60(23):6568-6572.
14. Gohji K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M. Expression of endothelin receptor a associated with prostate cancer progression. J Urol 2001;165(3):1033-1036.
15. Taub JS, Guo R, Leeb-Lundberg LM, Madden JF, Daaka Y. Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res 2003;63(9):2037-2041.
16. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3(8):582-591.
17. Charlesworth MC, Young CY, Miller VM, Tindall DJ. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid. J Androl 1999;20(2):220-229.
18. Xie Y, Gibbs TC, Mukhin YV, Meier KE. Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells. J Biol Chem 2002;277(36):32516-32526.
19. Barki-Harrington L, Daaka Y. Bradykinin induced mitogenesis of androgen independent prostate cancer cells. J Urol 2001;165(6 Pt 1):2121-2125.
20. Price DT, Rocca GD, Guo C, Ballo MS, Schwinn DA, Luttrell LM. Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 1999;162(4):1537-1542.
21. Raj GV, Barki-Harrington L, Kue PF, Daaka Y. Guanosine phosphate binding protein coupled receptors in prostate cancer. J Urol 2002;167(3):1458-1463.
22. Daaka Y. Mitogenic action of LPA in prostate. Biochim Biophys Acta 2002;1582(1-3):265-269.
23. Bookout AL, Finney AE, Guo R, Peppel K, Koch WJ, Daaka Y. Targeting Gbetagamma signaling to inhibit prostate tumor formation and growth. J Biol Chem 2003;278(39):37569-37573.
24. Kue PF, Daaka Y. Essential role for G proteins in prostate cancer cell growth and signaling. J Urol 2000;164(6):2162-2167.
25. Frantz B, O'Neill EA. The effect of sodium salicylate and aspirin on NF-kappa B. Science 1995;270(5244):2017-2019.
26. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C, Rabson AB. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002;52(3): 183-200.
27. Fukushima N, Chun J. The LPA receptors. Prostaglandins Other Lipid Mediat 2001;64(1-4):21-32.
28. Kue PF, Taub JS, Harrington LB, Polakiewicz RD, Ullrich A, Daaka Y. Lysophosphatidic acid-regulated mitogenic ERK signaling in androgen-insensitive prostate cancer PC-3 cells. Int J Cancer 2002;102(6):572-579.
29. Siehler S, Wang Y, Fan X, Windh RT, Manning DR. Sphingosine 1-phosphate activates nuclear factor-kappa B through Edg receptors. Activation through Edg-3 and Edg-5, but not Edg-1, in human embryonic kidney 293 cells. J Biol Chem 2001;276(52): 48733-48739.
30. Shahrestanifar M, Fan X, Manning DR. Lysophosphatidic acid activates NF-kappaB in fibroblasts. A requirement for multiple inputs. J Biol Chem 1999;274(6):3828-3833.
31. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2(7):489-501.
32. Lopez-Ilasaca M, Crespo P, Pellici PG, Gutkind JS, Wetzker R. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma. Science 1997;275(5298): 394-397.
33. Murga C, Laguinge L, Wetzker R, Cuadrado A, Gutkind JS. Activation of Akt/protein kinase B by G protein-coupled receptors. A role for alpha and beta gamma subunits of heterotrimeric G proteins acting through phosphatidylinositol- 3-OH kinasegamma. J Biol Chem 1998;273(30):19080-19085.
34. Yowell CW, Daaka Y. G protein-coupled receptors provide survival signals in prostate cancer. Clin Prostate Cancer 2002;1(3):177-181.
35. Glusac EJ, Shapiro PE, McNiff JM. Cutaneous T-cell lymphoma. Refinement in the application of controversial histologic criteria. Dermatol Clin 1999;17(3):601-614, ix.
36. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS Jr., Mayo MW. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 2000;20(5):1626-1638.
37. Huang S, Chen LY, Zuraw BL, Ye RD, Pan ZK. Chemoattractant-stimulated NF-kappaB activation is dependent on the low molecular weight GTPase RhoA. J Biol Chem 2001;276(44): 40977-40981.
38. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbalu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000;275(32):24500-24505.